GlycoMimetics, Inc. (NASDAQ: GLYC) today announced that Chief Executive Officer Rachel King will provide a company overview at two healthcare investor conferences next week, as follows:

STIFEL 2016 HEALTHCARE CONFERENCEWHEN: NOVEMBER 15, 2016 AT 4:30 PM ETWHERE: NEW YORK, NY, USA

JEFFERIES 2016 LONDON HEALTHCARE CONFERENCEWHEN: NOVEMBER 17, 2016 AT 1:20 PM GMTWHERE: LONDON, UK

To access the live webcast and subsequent archived recordings for the presentation, please visit the GlycoMimetics website at www.glycomimetics.com.

About GlycoMimetics, Inc.

GlycoMimetics is a clinical-stage biotechnology company focused on cancer and sickle cell disease. GlycoMimetics’ most advanced drug candidate, rivipansel, a pan-selectin antagonist, is being developed for the treatment of vaso-occlusive crisis in sickle cell disease and is being evaluated in a Phase 3 clinical trial being conducted by its strategic collaborator, Pfizer. GlycoMimetics’ wholly-owned drug candidate, GMI-1271, an E-selectin antagonist, is being evaluated in an ongoing Phase 1/2 clinical trial as a potential treatment for AML and in a Phase 1 clinical trial in multiple myeloma. GlycoMimetics has also recently initiated a clinical trial with a third drug candidate, GMI-1359, a combined CXCR4 and E-selectin antagonist. GlycoMimetics is located in Rockville, MD in the BioHealth Capital Region. Learn more at www.glycomimetics.com

GlycoMimetics, Inc.Investor Contact:Shari Annes, 650-888-0902sannes@annesassociates.comorMedia Contact:Jamie Lacey-Moreira, 410-299-3310jamielacey@presscommpr.com

GlycoMimetics (NASDAQ:GLYC)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more GlycoMimetics Charts.
GlycoMimetics (NASDAQ:GLYC)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more GlycoMimetics Charts.